Investigation of Ferritin in Critically Ill Patients With Hemophagocytic Lymphohistiocytosis — FERRITS  

Hemophagocytic Lymphohistiocytosis (HLH) Clinical Trial

Official title: The Prognostic and Diagnostic Value of Ferritin in Critically Ill Patients With Special Focus on Underlying Hemophagocytic Lymphohistiocytosis

Status Completed

Clinical Trial Summary

Retrospective analysis of ferritin, outcome and HLH-criteria in critically ill patients.

Clinical Trial Description

The study is a retrospective register study of critically ill patients from Charité - Universitätsmedizin Berlin during 2000 and 2016 that had at least one measurement of plasma ferritin. Outcome, underlying diagnoses and HLH-2004 criteria (Henter JI et al. 2007) will be analyzed and the HScore of these patients will be calculated (Fardet L et al. 2014). All recorded data of the specific admission term in ICU will be used for the analysis. No follow-up of the patients after discharge will be performed in this study. The study does not involve any randomization or any drug testing. Update 2019: We expanded our database for the years until 2018 and also for the surgical and medical ICUs of the Charité - Universitätsmedizin Berlin (from 256 to 2623 patients). Update 2022: A systematic literature search will be performed to find suitable validation cohorts for multicenter validation of optimized HLH diagnostic criteria, which are calculated based on our data (new secondary endpoint). ;

Related Conditions & MeSH terms

• Critical Illness
• Hemophagocytic Lymphohistiocytosis (HLH)
• Lymphohistiocytosis, Hemophagocytic
• Macrophage Activation Syndrome
• Syndrome

• NCT number: NCT02854943
• Study type: Observational
• Source: Charite University, Berlin, Germany
• Status: Completed
• Start date: January 2000
• Completion date: August 2018